Your browser doesn't support javascript.
loading
Endostatin, soluble tumour necrosis factor receptor 1 and soluble tumour necrosis factor receptor 2 cannot predict new onset of microalbuminuria in patients with type 2 diabetes.
Scurt, Florian G; Menne, Jan; Brandt, Sabine; Bernhardt, Anja; Mertens, Peter R; Haller, Hermann; Chatzikyrkou, Christos.
Afiliação
  • Scurt FG; Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
  • Menne J; Department of Nephrology, KRH Hospital Siloah, Klinikum Region Hannover GmbH, Hanover, Germany.
  • Brandt S; Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
  • Bernhardt A; Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
  • Mertens PR; Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
  • Haller H; Department of Nephrology, Hanover Medical School, Hanover, Germany.
  • Chatzikyrkou C; Department of Nephrology, Hanover Medical School, Hanover, Germany.
Diabetes Metab Res Rev ; 40(3): e3753, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38050450
ABSTRACT

AIMS:

Inflammation and angiogenesis play an important role in the development of early diabetic kidney disease. We investigated the association of soluble Tumour Necrosis Factor Receptor 1 (sTNF-R1), sTNF-R2 and endostatin with new onset microalbuminuria in normoalbuminuric patients with diabetes mellitus type 2.

METHODS:

We conducted a case control study to assess serum levels of sTNF-R1, sTNF-R2 and endostatin in 169 patients with new onset microalbuminuria and in 188 matched normoalbuminuric, diabetic controls. Baseline serum samples from participants of the ROADMAP (Randomized Olmesartan and Diabetes Microalbuminuria Prevention) and observational follow-up (ROADMAP-OFU) studies were used.

RESULTS:

Endostatin and sTNF-R1 but not sTNF-R2 were increased at baseline in patients with future microalbuminuria. In the multivariate analysis, each log2 increment in endostatin levels was associated with an increase of only 6% in the risk of development of microalbuminuria (adjusted HR (95% CI) 1.006 (1.001-1011). sTNF-R1 and sTNF-R2 levels were conversely associated with microalbuminuria, but the results did not reach statistical significance. The respective adjusted HRs (95% CI) were 1.305 (0.928-1.774) and 0.874 (0.711-1.074).

CONCLUSIONS:

sTNF-R1 and sTNF-R2 failed to predict the occurrence of microalbuminuria in normoalbuminuric patients with type 2 diabetes. Likewise, the utility of endostatin in predicting new onset proteinuria is limited.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas Limite: Humans Idioma: En Revista: Diabetes Metab Res Rev Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas Limite: Humans Idioma: En Revista: Diabetes Metab Res Rev Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha